H.C. Wainwright lowered the firm’s price target on Autolus Therapeutics (AUTL) to $8 from $11 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics reports inducement grants under Nasdaq listing rule
- Autolus Therapeutics Signs Long-Term Lentiviral Supply Agreement
- Autolus Therapeutics price target lowered to $8 from $10 at Truist
- Autolus: Short-Term Revenue Miss, Long-Term Blockbuster Potential Supports Buy Rating
- Maintaining Buy on Autolus: Solid Aucatzyl Growth and Extended Cash Runway Support Attractive Risk‑Reward Despite Lowered Targets